Organ Transplant System Expects Overhaul

The Nation's Organ Transplant System Expects To Be Overhauled Says HRSA

“Our goal is to get best in class for all the functions we think are essential to running the transplant network,” Johnson said. Who is “Johnson?” Well, Ms. Carole Johnson, is the Administrator of the federal Health Resources and Services Administration (HRSA), the agency responsible for the network, and she proposed breaking up the responsibility for some of the functions performed by its nonprofit manager, the United Network for Organ Sharing. UNOS is the only entity ever to operate the U.S. transplant system.

The United Network for Organ Sharing (UNOS) is a non-profit organization that manages the nation's organ transplant system in the United States. However, recently, there has been a push to break up the contract given solely to UNOS by the US Government Health Resources and Services Administration (HRSA).

The HRSA is the primary federal agency responsible for overseeing organ procurement and transplantation in the United States. In recent years, the agency has become increasingly concerned with the performance of UNOS and its ability to effectively manage the organ transplant system.

The organization has been criticized for its lack of transparency in decision-making processes and for not providing sufficient data to the public. According to The Wall Street Journal, Senator Charles E. Grassley (R-Iowa) is quoted as saying, “Thousands of patients are dying every year and billions of taxpayer dollars are wasted because of gross mismanagement,” “The system is rife with fraud, waste and abuse, corruption, even criminality.”

Patient advocates also lauded the plan. Greg Segal, founder, and CEO of Organize, a nonprofit patient advocacy group, said “UNOS has allowed the organ donation system to become mismanaged, unsafe, and self-enriching, according to the same WSJ article.

Another concern is the potential conflict of interest that UNOS has. The organization has a significant amount of influence over the allocation of organs for transplantation, which can lead to situations where patients in need may not receive organs due to various factors.

There have also been concerns raised about the effectiveness of UNOS in managing the organ transplant system. There have been reports of organs being wasted.

In response to these concerns, the HRSA has proposed breaking up UNOS’ contract and taking over responsibilities. The agency believes that by doing so, it will be able to increase transparency and accountability, reduce conflicts of interest, and improve the overall effectiveness of the organ transplant system.

However, there are also those who oppose the breakup of UNOS’ contract. Supporters of the organization argue that it has a long history of successfully managing the organ transplant system and that it is a crucial part of the healthcare system in the United States.

They also argue that the breakup of UNOS’ contract could lead to a fragmentation of the organ transplant system, making it harder for patients in need to receive organs. Additionally, they argue that the HRSA may not have the necessary expertise and resources to effectively manage the organ transplant system on its own.

In conclusion, the proposed breakup of UNOS’ monopoly contract by the US Government HRSA has generated significant debate in the healthcare community. There are certainly concerns about the organization's transparency and accountability. Ultimately, any decision made by the HRSA must consider the best interests of patients in need of organ transplants and ensure that the system is operating as effectively as possible.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


 

Did this answer your question?

 

More News

 

Kidney Products

 

Kidney Donation Boom: Bill Recommends Less Prison Time For Organ Donors

In recent years, the organ transplant shortage has become a significant problem worldwide. In an effort to increase the number of available organs, some countries are considering novel solutions, including the use of organs from convicted criminals. A recent bill in the United States seeks to incentivize organ donations among inmates by offering reduced sentences in exchange.

The bill proposes that eligible inmates who agree to donate a kidney or part of their liver would have their sentences reduced by up to five years. The reduced sentence would only be offered if the organ transplant is successful, and the recipient is deemed to have a significant improvement in their health.

The use of inmate organs for transplantation is not a new concept, and it has been done before in other countries. Proponents of the bill argue that it could help save lives and reduce the transplant waiting list. Inmates who participate would also benefit, as they would be able to return to society sooner.

However, critics argue that the bill raises ethical and moral concerns. They argue that it is wrong to exploit prisoners and incentivize them to donate their organs. Some also worry that the bill could lead to coercion and undue pressure on inmates to participate.

Advocates of the bill argue that offering reduced sentences to inmates who donate their organs could save lives and help ease the shortage of organs available for transplant. The shortage of organs is a significant problem, and many people die while waiting for a transplant. The use of inmate organs could help increase the number of available organs, giving more people a chance at a better life.

Moreover, the bill could benefit inmates themselves. By participating in the program, they would have the opportunity to reduce their sentence and return to society sooner. This could help them reintegrate into society and potentially turn their lives around, reducing the risk of recidivism.

On the other hand, opponents of the bill argue that it raises serious ethical and moral concerns. They argue that it is wrong to exploit prisoners and incentivize them to donate their organs. The bill could also lead to coercion and undue pressure on inmates to participate, particularly if they are offered reduced sentences as an incentive.

Furthermore, some critics argue that the bill could perpetuate existing inequalities in the healthcare system. They argue that it could prioritize the health of wealthy and influential individuals who are more likely to receive organs from inmates, at the expense of marginalized and low-income individuals who are less likely to receive organs.

In addition, there are also concerns about the quality of the organs being donated. Inmates may have health problems or lifestyle issues that could affect the quality of their organs, making them less suitable for transplantation. This could pose a risk to the recipients, who could suffer from serious medical complications as a result.

In conclusion, the recent bill proposing reduced sentences for organ donation among inmates is a complex issue with both potential benefits and drawbacks. The debate over the bill highlights the need for a comprehensive and ethical solution to the organ transplant shortage that prioritizes the welfare and rights of all involved, including the donor and the recipient.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


 

Did this answer your question?

 

More News

 

Kidney Products

 

Uncovering the Truth Behind Drug Price Hikes and How it Affects Kidney Disease, Dialysis, and Diabetes Patients

The high cost of prescription drugs has become a major concern for patients suffering from Chronic Kidney Disease (CKD) and those undergoing Dialysis. The burden of high drug prices is felt especially acutely by these patients, as they often require a range of medications to manage their condition and maintain their health. To address this issue, the US government has imposed penalties on drugmakers who raise their prices beyond the rate of inflation.

Drugmakers have come under fire for their pricing strategies, which have been criticized for being excessively high and placing a significant financial burden on patients. In response, the government has taken action to curb price hikes and ensure that drug prices remain affordable for all patients, including those with CKD and undergoing Dialysis.

Under the new regulations, drugmakers must provide justifications for any price increases that exceed the rate of inflation. The government can then penalize those who fail to provide a valid explanation, or who increase their prices excessively. Penalties may include fines, reduced Medicare and Medicaid reimbursement rates, and other consequences that can impact a drugmaker's bottom line.

For patients with CKD and those undergoing Dialysis, these penalties could result in lower drug prices and improved access to the medications they need. This will help to ensure that they receive the best possible care and are able to manage their condition effectively.

The penalties are a step in the right direction towards making prescription drugs more affordable for all patients. By taking action against drugmakers who engage in excessive price hikes, the government is working to ensure that patients with CKD and those undergoing Dialysis have access to the medications they need to maintain their health and manage their condition effectively.

In conclusion, the penalties for price hikes above inflation are a welcome move for CKD and Dialysis patients, as well as for all patients who rely on prescription drugs. By ensuring that drug prices remain affordable, patients can receive the care they need to manage their condition effectively, and enjoy a better quality of life.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


 

Did this answer your question?

 

More News

 

Kidney Products

 

Shocking News for CKD and Dialysis Patients: New Law Could Save You Thousands on Prescription Drugs - Here's How

Chronic kidney disease (CKD) and dialysis patients often have to manage a complex regimen of prescription drugs to maintain their health, but the cost of these drugs can be a significant burden. A new law passed in 2021 could change that and potentially save thousands on prescription drug costs for CKD and dialysis patients.

The new law expands the income limits for those who can receive extra help with their Part D costs, also known as the Medicare Prescription Drug Benefit. This means that more CKD and dialysis patients will now qualify for assistance, making it easier for them to afford the drugs they need.

To be eligible for the expanded assistance, CKD and dialysis patients must have a household income of less than or equal to 150% of the federal poverty level. They must also be enrolled in a Part D plan and have limited savings and resources.

The potential savings for those who qualify for the expanded assistance are significant, with an average of thousands of dollars per year on prescription drug costs. This is a huge relief, particularly for CKD and dialysis patients who already have to deal with high medical costs.

CKD and dialysis patients often have to manage multiple prescriptions and the cost of these drugs can be a significant burden, but now, with this new law, they can get the extra help they need to cover the costs. Don't miss out on this opportunity to save thousands on your prescription drugs costs, check your eligibility and apply for the expanded assistance today.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


 

Did this answer your question?

 

More News

 

Kidney Products

 

New Breakthrough Discovery: Kidney Disease and Dialysis Patients Can Save THOUSANDS on Insulin Costs - Find Out How!

Are you tired of struggling to afford the high cost of insulin as a kidney disease or dialysis patient? Look no further! A new program from the Centers for Medicare and Medicaid Services (CMS) could potentially save you thousands of dollars on your insulin costs.

Insulin is a crucial medication for those with kidney disease and those undergoing dialysis, as it helps regulate blood sugar levels and prevent complications such as diabetic ketoacidosis. However, the cost of insulin has skyrocketed in recent years, making it increasingly difficult for many patients to afford.

The exciting new program, announced by CMS in early 2021, aims to alleviate the financial burden of insulin costs for Medicare beneficiaries. Dialysis facilities will now be able to purchase insulin at a discounted rate and pass the savings on to patients.

To qualify for this game-changing program, patients must be enrolled in Medicare and receive dialysis treatments at least three times a week. They must also have a prescription for insulin and be responsible for paying a portion of the cost of the medication.

The potential savings for eligible patients is astounding, with an average of thousands of dollars per year on insulin costs. This is a life-changing amount, especially for those living on a fixed income or with high out-of-pocket healthcare expenses.

Not only will this program provide financial relief, but it can also greatly improve patients' health outcomes by making it more likely for them to afford the insulin they need. Poor blood sugar control and an increased risk of complications can be avoided with the proper use of insulin.

Don't miss out on this incredible opportunity to save thousands on your insulin costs as a kidney disease or dialysis patient enrolled in Medicare. Contact your dialysis facility and inquire about the program today!


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


 

Did this answer your question?

 

More News

 

Kidney Products

 

Fresenius taps pre-dialysis kidney care as drugs promise treatment change

The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes early on.

For decades, Germany's Fresenius Medical Care (FMC) (FMEG.DE) has been the biggest player in the $50 billion U.S. market providing dialysis and related machines that help filter out blood toxins for people whose kidneys have failed to function.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


Future of Health

6 minute readOctober 5, 20226:49 AM PDTLast Updated 2 days ago

Fresenius taps pre-dialysis kidney care as drugs promise treatment change

By Ludwig Burger

1/2

Diabetes drug Farxiga (dapagliflozin) is displayed at a pharmacy in Provo, Utah, U.S. May 28, 2020. REUTERS/George Frey/File Photo

  • Summary

  • Companies

  • New diabetes drugs also shown to slow kidney decline

  • Dialysis company FMC sees impact on its grow outlook

  • Fresenius Medical in push into earlier stages of kidney disease

  • Separate <a href="/business/healthcare-pharmaceuticals/new-treatments-hold-promise-slowing-kidney-damage-2022-10-05/">Reuters factbox gives details of new drugs</a>

FRANKFURT, Oct 5 (Reuters) - The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes early on.

For decades, Germany's Fresenius Medical Care (FMC) (FMEG.DE) has been the biggest player in the $50 billion U.S. market providing dialysis and related machines that help filter out blood toxins for people whose kidneys have failed to function.

Advertisement · Scroll to continue

The company’s 17.6 billion euros ($17.6 billion) in annual revenue has been sustained for decades by high rates of obesity and diabetes, which contribute to kidney damage.

But the dialysis market is changing as new medications have been shown to dramatically improve the conditions that lead to kidney failure.

FMC anticipates that the introduction of these drugs could be a drag on its patient population growth for at least some years. To diversify its revenue base it is pushing to expand beyond its core dialysis business into the care of earlier stage kidney disease.

The new drugs include AstraZeneca's (AZN.L) Farxiga diabetes pill that also delivers benefits for non-diabetics as an approved treatment to slow chronic kidney disease (CKD).

Germany’s Boehringer Ingelheim and Eli Lilly's (LLY.N) Jardiance diabetes drug is expected to be used for the same purpose, while Novo Nordisk's (NOVOb.CO) Wegovy injection offers a new treatment option for obesity. Other similar new treatments such as Eli Lilly’s (LLY.N) Mounjaro are also expected to offer new weight loss options.

They all add pressure to the dialysis industry which faces rising costs and a temporary shrinking of its patient pool, particularly in the United States.

More than 15,000 people on dialysis are estimated to have died of COVID in 2020 alone, according to the U.S. Renal Data System. A labour shortage in the U.S. healthcare market has pushed wages higher and forced FMC, which derives about 70% of its revenue from the United States, and other dialysis providers to rely more on temporary staff.

A U.S. Supreme Court ruling has also shifted how much kidney care coverage private insurers and the government must offer.

The pressures have pushed FMC's shares to a near 13-year low and analysts expect the company’s adjusted net income to decline 14.5% to 870 million euros this year.

Parent company Fresenius SE (FREG.DE) has said a sale of FMC could not be ruled out.

For now though, FMC is trying to reposition itself in the market and sees hope for the company and patients alike: the new drugs, by slowing the progression of disease, should prolong the lives of those who do eventually need dialysis, keeping patients in FMC's care for longer, Frank Maddux, FMC's global chief medical officer, told Reuters.

“In the short run, we'll see the impact of some delayed (chronic kidney disease) progression but in the longer run, we're probably going to see an expansion of the number of people with chronic kidney disease that survive to live with the disease," said Maddux.

Sabastien Buch, a fund manager at Union Investment in Frankfurt, Germany, which holds FMC shares, agreed that even if fewer people end up needing dialysis, those who do are likely to live longer, thanks to the new drugs.

"Patients that start dialysis in better health will not pass away after four or five years, but will be part of a group that remain on therapy for maybe seven or eight years, which are rather rare cases today," said Buch.

 

Did this answer your question?

 

More News

 

Kidney Products

 

Doctors push state to cover dialysis for undocumented immigrants

When Lauren Kasper was starting her career as a nurse practitioner, one of her patients, a 30-year-old father who had come to the emergency room for dialysis, died “a slow, horrible death.”

The worst part, Kasper said, was that the man’s death was avoidable.

“I decided, I can’t sit here, knowing we can do something,” she said “Watching people die like this, it’s so pointless.”

The young father died of kidney failure after waiting too long to get dialysis. As an undocumented immigrant, he was not eligible for insurance under the Affordable Care Act or for Medicaid and had no way to pay for what should have been routine and regular treatment.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


Although the death happened years ago, immigrants today continue to suffer from the same situation. Kasper, now a hospital administrator, and other physician advocates across Georgia are working to convince state officials to make changes to address the dangerous and costly gap in care.

Up to 800 undocumented immigrants living in Georgia at any given time require dialysis, said Dr. Shamie Das, physician at the Emory University Hospital emergency department. Many undocumented dialysis patients show up at emergency rooms with health problems like shortness of breath or even cardiac arrest due to not receiving dialysis when needed, Dr. Das said.

For people whose kidneys don’t filter blood the way they should, dialysis is a treatment that removes wastes, toxins and excess fluid from the blood. People with kidney failure who don’t receive routine dialysis not only experience multiple health problems, their mortality rate within five years of initiating treatment is more than 14 times higher than those who do, according to research.

A federal law requires hospitals to treat anyone who comes to the emergency room, even when they can’t pay for their care. Treating dialysis patients in emergency rooms can cost up to $400,000 per patient each year — or about four times what outpatient dialysis would cost if done on a regular basis, according to a 2020 article in the American Journal of Kidney Diseases. Despite the federal law requiring hospitals to provide emergency care, hospitals aren’t reimbursed and some of those costs are borne by taxpayers. Some are written off as charity care. Some contribute to rising insurance and healthcare costs, according to experts.

During the pandemic, the situation has also created additional problems for short-staffed, overloaded emergency rooms, contributing to longer wait times for all patients, as well as exposing dialysis patients to the virus.

Kasper, Dr. Das and colleagues are pushing to have Georgia cover the cost of routine dialysis. In Georgia’s Medicaid system, a program known as “Emergency Medical Assistance,” could be expanded to allow healthcare facilities to be reimbursed for routine dialysis treatments for undocumented immigrants.

The move would not only improve and even save lives, say Kasper and her colleagues, but be more cost-effective, saving public and private hospitals tens of millions a year. At least 12 states have adopted similar measures — including those like Arizona, with large undocumented immigrant populations.

Dr. Josh Mugele, emergency medicine program director at Northeast Georgia Medical Center, supports the idea. Earlier this year, paramedics brought a patient in his 20′s to one of the hospitals where he works. The man had suffered a heart attack at a shopping center. “Cardiac arrest is unusual for people in their 20s,” said Dr. Mugele. “I didn’t think immediately of him missing dialysis ... but it became apparent pretty quickly that the patient had too much potassium in his blood, a condition that occurs in renal disease. We were able to treat and resuscitate him.”

Dr. Mugele later discovered the patient lived several hours away, was undocumented, and only received occasional dialysis. He had suffered a previous heart attack. “Imagine if he continues this way,” Dr. Mugele said. “He will collapse somewhere where there won’t be bystanders.”

The emergency doctor said he has seen similar cases “dozens of times” in his three years working in Georgia.

Dr. Das and Kasper are completing research on the issue for submission to a peer-reviewed journal. They did a survey involving 90% of the hospitals in Georgia and estimate that there are 500 to 800 undocumented immigrants who are dialysis patients across Georgia at any one time.

Another voice in support of a change comes from the Medical Association of Georgia, a group representing physicians. The association passed a resolution late last year in support of pursuing a “fiscally responsible” change to state Medicaid or other government programs to cover routine dialysis for undocumented patients, said Bethany Sherrer, director of government relations and general counsel.

Dr. Liliana Cervantes cared for a patient who she then befriended until the woman died in 2014 after being unable to obtain regularly scheduled dialysis. The internal medicine hospitalist set about seeking a change in her state of Colorado. It took a few years, but the state moved in 2019 to include scheduled dialysis for undocumented immigrants under Emergency Medicaid. Now, Dr. Cervantes informally advises medical colleagues in five states seeking to do the same, including Georgia.

In her experience, she said, “every environment has policymakers who are polarized. It’s important to understand factors that would influence their decision-making. In Colorado, the most important factor was cost.” Dr. Cervantes added that “not only does emergency dialysis cost more — people are able to rejoin the workforce more quickly and contribute to the tax base if they receive regularly scheduled dialysis. So it’s a win-win for everyone.”

Kasper said she hopes Jerry Dubberly, state Medicaid division chief, makes the change without needing the state Legislature to act, but realizes the issue may require changing Georgia code. Officials at Grady Memorial Hospital said they are “in communication” with the Department of Community Health, which oversees Medicaid, about “policies in other states” that have addressed undocumented immigrants with kidney failure.

The issue is not new in Georgia, she noted: in 2010, Grady, Emory and private dialysis centers agreed to cover treatment for a small group of undocumented patients and sent a smaller group back to Mexico. Nearly half of the second group died.

But now, the problem is more acute, not only because the population of undocumented immigrants has grown, but because the emergency room has become a much-needed, limited resource each time there’s a surge in COVID cases. “I’ve seen this problem get worse during the pandemic — when we’re resource short,” said Kasper.

The situation has contributed to what Dr. Das called “moral injury,” a concept described by one researcher as “a deep emotional wound ... unique to those who bear witness to intense human suffering and cruelty.” Moral injury in healthcare workers has been described as prevalent inresearch on this issue, and has also increasingly surfaced during the pandemic.

“They cry. You cry. You see patients deteriorate so quickly,” Kasper said. “The ones who are still alive are in terrible condition. It’s really hard to watch.”

Reference: AJC.com

 

Did this answer your question?

 

More News

 

Kidney Products

 

For-profit dialysis facilities correlate with increased time to wait-listing, transplant

Pediatric patients who received care at for-profit dialysis facilities experienced significantly longer time for placement on the waitlist and receipt of a kidney transplant compared with those who received care a nonprofit facility.

“Studies have shown that receipt of maintenance dialysis at profit facilities was associated with lower rates of transplant and worse survival among adults with end-stage kidney disease,” Sandra Amaral, MD, MHS, from the Children’s Hospital of Philadelphia and University of Pennsylvania, and colleagues wrote. They added, “This study examined the association between the profit status of U.S. dialysis facilities and the amount of time it took for pediatric patients with ESKD to be placed on the waiting list and receive a transplant.”


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


In a retrospective cohort study, researchers examined 13,333 patients younger than 18 years old (median age was 12 years; 45% were girls; 25% were “non-Hispanic Black” patients; 28% were Hispanic patients) who initiated dialysis between 2000 and 2018 in United States facilities. Data were derived from the U.S. Renal Data System.

Researchers identified the profit status of facilities using a combination of the type of ownership and for-profit or nonprofit variables from the facility file. Additionally, the status of a patient’s facility was updated whenever a patient switched from a facility with one status to a facility with another status.

Among the cohort, 60% were treated at a nonprofit facility, 27% at a profit facility and 13% switched facilities with status. Moreover, 75% of the cohort were registered on the wait list during the study and follow-up period and 69% received a kidney transplant.

Analyses revealed that during a median follow-up of 0.87 years, the occurrence of wait-listing at profit facilities was 36.2 per 100 person years and was 49.8 per 100 person years at nonprofit facilities. Similarly, a median follow-up of 1.52 years revealed the incidence of kidney transplant, whether living or deceased donor, was also lower at profit facilities than at nonprofit facilities, 21.5 vs. 31.3 per 100 person-years, respectively.

Using Cox proportional models, researchers measured time to waitlist and receipt of kidney transplantation by profit status of dialysis facilities. Models were adjusted for clinical and demographic factors.

In an accompanying editorial, Mary B. Leonard, MD, MSCE,and Paul C. Grimm MD, from Stanford University School of Medicine, wrote, “The substantial association between nonprofit dialysis facility ownership and greater access to transplants among pediatric patients likely reflects greater clinician experience with the special needs of pediatric patients with ESKD and their families, as well as more robust facility-level processes and structures needed to care for these vulnerable patients.”

They added, “Improving access to kidney transplants, availability, and outcomes for underrepresented groups with ESKD will require collecting national surveillance data on early steps to identify and overcome patient-level, clinician-level and system-level barriers to kidney transplants. These efforts also should include measures of interdisciplinary pediatric nephrology expertise. Pediatric patients may be a small part of the national transplant equation, but they have the most to gain.”

Reference:

Improving quality of care and outcomes for pediatric patients with end-stage kidney disease: The importance of pediatric nephrology expertise. https://jamanetwork.com/journals/jama/article-abstract/2794784 Published: Aug. 2, 2022. Accessed: Aug. 8, 2022.

 

Did this answer your question?

 

More News

 

Kidney Products

 

U.S. accuses Fresenius Medical Care unit of fraud in dialysis treatment

The United States has joined a whistleblower lawsuit accusing a unit of Germany's Fresenius Medical Care AG (FMEG.DE) of defrauding Medicare and other healthcare programs by billing for medically unnecessary procedures on dialysis patients.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


According to a civil complaint filed late Tuesday night, Fresenius Vascular Care violated the federal False Claims Act by routinely performing the procedures on patients with end-stage renal disease at nine facilities in New York City and its suburbs from January 2012 to June 2018.

 

The U.S. Department of Justice said Fresenius knowingly conducted angioplasties and fistulagrams, which both involve insertions or injections into veins and arteries, to drive up revenue and help the facilities meet performance metrics.

Many patients who received the procedures were elderly, low-income or disadvantaged minorities, the department said.

In a statement, Fresenius said it disputed the accusations and intended to vigorously defend itself. "Our policies are intended to result in a high standard of care and compliance with government regulations," the company added.

End-stage renal disease occurs when a person's kidneys stop functioning normally, requiring dialysis or kidney transplants.

The Justice Department said Fresenius knew its procedures "exposed patients to grave risks" including over-sedation, infection, blood vessel ruptures or conditions that could require more invasive or frequent treatment.

In a statement, U.S. Attorney Breon Peace in Brooklyn called Fresenius' conduct "egregious."

The lawsuit was originally filed in June 2014 by two doctors, John Pepe of the New York City borough of Staten Island and Richard Sherman of Westfield, New Jersey, court papers show.

Pepe, in a statement, said Fresenius "put patients in harm's way to support their bottom line."

The False Claims Act lets whistleblowers sue on behalf of the federal government, and share in recoveries.

The case is U.S. ex rel. Pepe et al v Fresenius Vascular Care Inc, U.S. District Court, Eastern District of New York, No. 14-03505.

 

Did this answer your question?

 

More News

 

Kidney Products

 

Supreme Court dialysis ruling sets stage for coverage limits

The U.S. Supreme Court on Tuesday rejected dialysis provider DaVita Inc's (DVA.N) claims that an Ohio hospital's employee health plan discriminates against patients with end-stage kidney disease by reimbursing them at low rates in hopes they would switch to Medicare.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


In a 7-2 decision authored by conservative Justice Brett Kavanaugh, the court ruled that Marietta Memorial Hospital's employee health plan did not violate federal law by limiting benefits for outpatient dialysis because it did so without regard to whether patients had end-stage renal disease. A lower court had ruled in favor of Denver-based DaVita.

 

Did this answer your question?

 

More News

 

Kidney Products

 

Music therapy eased depression, anxiety symptoms in patients on dialysis

Photo by Lovefreund

Music therapy improved depression and anxiety symptoms among patients on dialysis, according to an award-winning poster presented here.

“I did research on music therapy and found it to be incredibly potent in Asia and the Middle East, but there aren’t a lot of studies done in America. This is the first time we studied music therapy in a clinic where we accessed the generalized anxiety disorder (GAD) and patient health questionnaire (PHQ),” Janavi Kolpekwar, the lead author of the study and a high school senior from Round Rock High School in Texas, told Healio. The research was presented in a poster session at the National Kidney Foundation Spring Clinical Meetings.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


In their quality improvement project, Kolpekwar and researchers obtained consent from six patients receiving dialysis at the clinic in Texas before conducting the study. At baseline, researchers collected PHQ-9 depression scale and GAD-7 anxiety scale results from all patients. Then, researchers offered each patient a color-coded flash drive with 40 minutes of music at the beginning of dialysis treatment for 5 weeks. Music genres uploaded to the flash drive included opera, Latino, country, soul, pop and classic rock. 

After 5 weeks of music therapy, researchers collected post-test PHQ-9 depression scale and GAD-7 anxiety scale results and compared these with pre-test results.

Results revealed the average PHQ-9 score among patients prior to music therapy was 4.8 and was 3.2 afterward. Similarly, the average GAD before music therapy was 4.5 and was 3.3 afterward. 

“The feedback was positive. Some people came back saying, ‘I want more music options.’” Kolpekwar told Healio. She added, “Hopefully, more clinics and hospitals can implement music therapy and maybe even have a live music therapist.” 

According to the study, music therapy may also have positive effects on other medical and social parameters, such as blood pressure and compliance with dialysis treatment. However, a reliable randomized control trial is needed with a larger pool of patients and consideration of confounding variables, the researchers noted.

Editor’s note: The article was updated on April 13, 2022, to correct the name of the presenter's school. The Editors regret the error.

 

Did this answer your question?

 

More News

 

Kidney Products

 

Milk Alternatives for People with Chronic Kidney Disease

“got milk?®” This phrase, developed by the California Milk Processor Board, became one of the most recognized slogans in advertising history. The campaign features numerous celebrities and cultural icons crediting milk for their strong bones and muscle health.

Yet people with chronic kidney disease (CKD) have to limit dairy products in their kidney diet. High levels of phosphoruspotassium and calcium in something like low-fat milk are not good for someone on a kidney diet.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


But isn’t milk good for my bones?

Bones are mostly made of calcium and phosphorus. When kidneys function well, they are able to keep these two minerals in balance in the blood and bones. However, kidney disease causes this process to become dysfunctional:

  • Excess phosphorus builds up in the blood.

  • Kidneys no longer activate vitamin D, which affects the ability to absorb calcium from food eaten.

  • Low blood calcium levels release cause calcium and phosphorus from the bones, weakening them over time.

  • Increased phosphorus in the blood combines with calcium, causing calcifications elsewhere in the body and decreases the amount of blood calcium.

Despite milk’s calcium content, its high phosphorus content may actually weaken bones.

There is calcium in both hemodialysis and peritoneal dialysis (PD) solutions, so patients receive some of their daily calcium requirements with their dialysis treatments. Some phosphate binders also contain calcium. Therefore, it is unusual for a dialysis patient to get insufficient amounts of calcium.

Are there any alternatives to milk if I have kidney disease?

Yes. Soy milk, rice milk and almond milk can be found in most grocery stores, while other milk alternative products have also gained in popularity. However, some of these products do contain significant amounts of potassium and/or phosphorus, so it’s important to check labels. Do not assume a product is low in potassium or phosphorus because values are not listed on the label. For example, one brand of hemp milk contains 450 mg of phosphorus in one cup. This is almost half the recommended 1,000 mg phosphorus limit.

At one time nondairy creamers were included as a milk alternative choice. Unfortunately, the phosphate and potassium additives in many nondairy creamers has changed the recommendation to include in a kidney diet.

What should I consider in choosing a milk alternative?

Consider calcium, phosphorus, potassium and protein content when choosing a milk alternative. Your dietitian can help you determine which milk alternative is right for your diet. Unfortunately, only calcium and protein are usually listed on food labels. Potassium will be required in the future. The ingredient list often gives clues to help when selecting a milk alternative. Products with phosphate additives would not be the best choices. Many of these substitutes contain added calcium. Your dietitian can help guide you on the right product if you need to limit calcium.

Be aware that product formulas can change. One brand of soy milk that is low in phosphorus may be fortified with phosphorus the following year. Even within the same brands, different flavors can have varied amounts of phosphorus, calcium and potassium. It often helps to contact the company directly to get the most current nutritional information. Here are some milk alternatives that people with kidney disease may consider using in their diets:

Rice milk

  • Rice Dream Rice Drink Original Classic

  • Rice Dream Rice Drink Vanilla Classic

Soy milk

  • Edensoy Light Vanilla Soy Milk

  • Edensoy Light Original Soy Milk

  • Pacific Select Soy Low Fat Plain

  • Pacific Select Soy Low Fat Vanilla

  • Soy Dream Classic Vanilla

Almond milk

  • Almond Breeze, Unsweetened Original

  • Almond Breeze, Unsweetened Vanilla

  • Almond Breeze, Unsweetened Almond-Coconut

  • Pacific Organic Almond Unsweetened Low Fat Original

  • Pacific Organic Almond Unsweetened Low Fat Vanilla

  • Pacific Organic Almond Original

  • Pacific Organic Almond Vanilla

  • Silk, Unsweetened Original

  • Silk, Unsweetened Vanilla

What types of meals can I make with my milk alternatives?

Here are some yummy DaVita.com recipes to choose from:

Breakfast

Lunch

Dinner

Dessert

Beverages

 

Did this answer your question?

 

More News

 

Kidney Products

 

Former nurse found guilty in accidental injection death of 75-year-old patient

RaDonda Vaught, a former nurse criminally prosecuted for a fatal drug error in 2017, was convicted of gross neglect of an impaired adult and negligent homicide on Friday after a three-day trial in Nashville, Tenn., that gripped nurses across the country.

Vaught faces three to six years in prison for neglect and one to two years for negligent homicide as a defendant with no prior convictions, according to sentencing guidelines provided by the Nashville district attorney's office. Vaught is scheduled to be sentenced May 13, and her sentences are likely to run concurrently, said the district attorney's spokesperson, Steve Hayslip.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


Vaught was acquitted of reckless homicide. Criminally negligent homicide was a lesser charge included under reckless homicide.

Vaught's trial has been closely watched by nurses and medical professionals across the U.S., many of whom worry it could set a precedent of criminalizing medical mistakes. Medical errors are generally handled by professional licensing boards or civil courts, and criminal prosecutions like Vaught's case are exceedingly rare.

Janie Harvey Garner, the founder of Show Me Your Stethoscope, a nursing group on Facebook with more than 600,000 members, worries the conviction will have a chilling effect on nurses disclosing their own errors or near errors, which could have a detrimental effect on the quality of patient care.

"Health care just changed forever," she said after the verdict. "You can no longer trust people to tell the truth because they will be incriminating themselves."

In the wake of the verdict, the American Nurses Association issued a statementexpressing similar concerns about Vaught's conviction, saying it sets a "dangerous precedent" of "criminalizing the honest reporting of mistakes." Some medical errors are "inevitable," the statement said, and there are more "effective and just mechanisms" to address them than criminal prosecution.

"The nursing profession is already extremely short-staffed, strained and facing immense pressure — an unfortunate multi-year trend that was further exacerbated by the effects of the pandemic," the statement said. "This ruling will have a long-lasting negative impact on the profession."

Vaught, 38, of Bethpage, Tenn., was arrested in 2019 and charged with reckless homicide and gross neglect of an impaired adult in connection with the killing of Charlene Murphey, who died at Vanderbilt University Medical Center in late December 2017. The neglect charge stemmed from allegations that Vaught did not properly monitor Murphey after she was injected with the wrong drug.

Murphey, 75, of Gallatin, Tenn., was admitted to Vanderbilt for a brain injury. At the time of the error, her condition was improving, and she was being prepared for discharge from the hospital, according to courtroom testimony and a federal investigation report. Murphey was prescribed a sedative, Versed, to calm her before being scanned in a large MRI-like machine.

Vaught was tasked to retrieve Versed from a computerized medication cabinet but instead grabbed a powerful paralyzer, vecuronium. According to an investigation report filed in her court case, the nurse overlooked several warning signs as she withdrew the wrong drug — including that Versed is a liquid but vecuronium is a powder — and then injected Murphey and left her to be scanned. By the time the error was discovered, Murphey was brain-dead.

 

Did this answer your question?

 

More News

 

Kidney Products

 

Dialysis Patient Col. James Manning Living Life To The Fullest

At age 90, retired Col. James Manning has lived such a full life it’s like he is more than one person.

He served in the U.S. Army, rose to the rank of colonel in the Army Reserves, worked as a technical writer at Boeing, a teacher at the former Asa Mercer Junior High School in Seattle, a salesman for IBM, and eventually retired from the Washington State Higher Education Coordinating Board. He’s active in his church, has been married two times, and has 13 children, 10 grandchildren, and nine great-grandchildren.

Along the way, he adopted a family of Vietnamese refugees and is proud to count the children, grandchildren and great-grandchildren of that family as his own.

He’s lived a good life. A fulfilling life. One that sets a stellar example for others.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


But Manning acknowledges that as the decades passed, he sometimes ignored his health. He gained weight – tipping the scale at 260 pounds at one point. He didn’t always eat healthy food or exercise. He also failed to recognize his family’s history with diabetes and high blood pressure.

Diabetes and high blood pressure are the two leading causes of kidney disease and when Manning was around age 65 and was preparing to retire, he learned that his kidneys were weakening and likely would eventually fail. He was doing some financial planning and considered buying life insurance. He went through a physical exam and learned he would be rejected for the insurance because he had chronic kidney disease.

“I was devastated by this,” said Manning, who like many others with kidney disease was completely surprised by his diagnosis. Fifteen percent of Americans have chronic kidney disease, and 90 percent don’t know it because kidney damage usually occurs without symptoms. Worldwide it affects 850 million people and is the 11th leading cause of global mortality.

March is National Kidney Month and a time to focus on kidney disease and its causes. Other risk factors include heart disease, smoking, and family history of kidney disease. Those who are African American, Asian American or Native American, people who are overweight, and those over age 60 are at higher risk for developing kidney disease.

Manning’s doctor gave him medication, told him to reduce the salt in his diet, and drink more water and cranberry juice to flush his kidneys. He followed his doctor’s advice and was able to slow progression of kidney failure. However, by 2004 his kidneys had weakened to the point where he needed dialysis because they could no longer clean the waste and water from his system.

“I was scheduled for my first dialysis session at the Auburn clinic at 5:30 Sunday morning, March 14. I never will forget it,” he said.

Manning initially received dialysis treatments three times a week, for four hours at a time, at Northwest Kidney Centers’ clinic in Auburn. Then he heard that he could get dialysis at home and learned how to do it himself. Home dialysis is preferred because patients can dialyze more often and for longer periods of time, which is easier on the body.

He continued to dialyze at home for 11 years and even was able to travel with his portable dialysis machine, enjoying trips around Oregon, Washington, Florida, Washington, D.C., and the Caribbean. He had the freedom to continue to live a full life.

But in his ‘80s he returned to in-center dialysis treatments, this time choosing the new Northwest Kidney Centers’ Federal Way East clinic. Throughout his relationship with kidney disease and Northwest Kidney Centers, being a patient wasn’t enough for Manning. After starting dialysis, he became an active volunteer for the non-profit dialysis provider, serving on its board of trustees for 12 years, and lobbing for dialysis patients in Washington, D.C. He participated in a Facebook group for home hemodialysis patients, offering advice based on his experience. And he has enthusiastically supported Northwest Kidney Centers’ annual fundraisers, even speaking on behalf of patients at the 2017 Breakfast of Hope event.

Despite his challenges with kidney disease and other health issues, Manning remains upbeat and involved. “I’ve been kicking right along,” he said.

 

Did this answer your question?

 

More News

 

Kidney Products

 

10 strangers come together for a life-changing kidney swap

Michael Wingard arrives at Houston Methodist Hospital with a cheerful "Howdy!" He's a rangy young man with a scrub-brush of a beard, and a healthy left kidney that's where it's always been – safely tucked up just below his rib cage. 

In a couple of hours a surgeon will remove the kidney and sew it into someone else's body. 

This also happens to be the day before his 20th birthday. 

"I'm barely even thinking about that," Michael tells NPR. "No cake, unfortunately. It'll be like Jell-O or something like that." 

The Wingard family is from Kerrville, Texas, about four hours west of Houston. Michael's parents, Adrien and Ed, are with him, and they tear up as Michael is checked in. 

"I'm very, very nervous and scared and all those emotions, but I'm so proud of him," Adrien Wingard says. "He knew that his friend needed a kidney and he had to do whatever it took to make it happen."


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


And that's how Wingard became the first link in a 10-person chain that took place at Houston Methodist earlier this month. 

In addition to Wingard, the swap involved: 

  • Heather O'Neil Smarrella, who will get his kidney. Then her twin

  • Staci O'Neil gave her kidney to

  • Javier Ramirez Ochoa, whose son-in-law

  • Tomas Martinez, donated a kidney to

  • Chris McLellan, whose father

  • David McLellan, gave his kidney to

  • Barbara Moton, whose daughter

  • Lisa Jolivet, gave her kidney to

  • Kaelyn Connelly, Wingard's friend.

This 10-person procedure takes place over four days, and it's uncommon. The last one at Houston Methodist was in 2020. Usually the hospital has chains that involve up to six people.

With all its complexities – from matching antibodies to patient health – a kidney swap of this size is hard to pull off. This one was postponed three times. 

But it's worth the effort. 

There are about 90,000 people on the Organ Procurement and Transplantation Network list, waiting for a kidney. Many will remain on the list for years. Some die waiting. 

Transplanting kidneys from living donors greatly increases the number of kidneys available. Additionally, a kidney from a living donor functions for 12 to 20 years, on average, while a kidney from a deceased donor works for about 8 to 12 years. 

Alternative to 'dialysis or death'

Dr. Richard Link, Michael Wingard's surgeon, arrives a few hours after Wingard checks in to explain the surgery will be laparoscopic; he'll remove the left kidney through a 2-inch long incision in the abdomen. Dr. Link describes this as a relatively routine operation. 

"You'll be surprised that we can get a kidney out of the size of the hole that we make," he says. "It's a little bit of a magic trick." 

When a nurse comes to take Michael Wingard to the operating room, his parents hold each other's hands. 

"Rock it, buddy," his father says into his ear.

 

While Wingard is getting wheeled down the hall, Heather O'Neil Smarrella is getting prepped to receive his kidney, and Lisa Jolivet is just settling into her room. 

The 43-year-old from Houston has an easy, infectious laugh. Even though it's the night before her surgery, she's cracking up at jokes about Jell-O shots, the Astros and "crap" kidneys. Jolivet is here because her mother, Barbara Moton, who loves casinos and her grandchildren, learned that she was in renal failure in 2019. 

"She had kind of said, 'This is my fate. These are my cards,'" Jolivet says. 

Before Moton arrived at Houston Methodist, her doctors told her she only had two options: dialysis or death. Her daughter refused to accept that, and researched a third option: a living donor transplant. She made her mom a pinky swear. 

"If you're denied, we'll never say anything about it," Jolivet told her. "You don't have to do dialysis, and you can just ride out into the sunset." 

But Moton passed every test and got approved for a kidney transplant in August 2021. Source: NPR

 

Did this answer your question?

 

More News

 

Kidney Products

 

Plan for non-nursing staff, industry to conduct home dialysis training ‘dangerous’

The American Nephrology Nurses Association is criticizing a position paper released by a kidney community advocacy group that is proposing non-nursing personnel and dialysis manufacturers provide home dialysis training.

“We cannot imagine a potentially more compromised approach to ensuring competent, qualified home dialysis care,” Dave Walz, MBA, BSN, RN, CNN, FACHE, president of ANNA, said in a press release. “ANNA works tirelessly in the support of advocating only sound educational programs that are optimized to develop, maintain and deliver high-quality kidney care.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


“We actively support a cross-disciplinary team approach to patient care and wellness and, while we support interdisciplinary collaboration in delivering high-quality, cost-effective kidney care, we are deeply concerned with the recommendations reflected in the position paper in question,” Walz said.

Members of Innovate Kidney Care (IKC), which released the paper on March 3, include dialysis machine manufacturers, health plans, the National Kidney Foundation and the American Society of Nephrology. The paper is directed at making changes on how home dialysis training is conducted under the Conditions for Coverage, a set of federal rules dialysis providers must follow to receive Medicare reimbursement for patient care. 

CMS last revised the regulations in 2008.

Manufacturers’ role

The IKC position paper recommends that CMS “remove the requirement that RNs ‘conduct’ the (home) training, replacing it with ‘having more oversight and participation by a[n]’ RN who can then determine readiness.” Also, the paper proposes manufacturers be allowed to provide patient education. 

“CMS should permit home dialysis device manufacturers to directly train patients, under the oversight of the dialysis facility nurse,” the authors wrote. “As more new machines come to market, it is imperative that manufacturers be able to train patients on how to use such machines.”

ANNA, which has more than 8,000 members, said it “strongly disagrees” with the idea of allowing industry personnel to educate patients on home dialysis, saying “the call for an emerging reliance upon home dialysis device manufacturers to directly train patients, under the oversight of a dialysis facility nurse, presents a framework for a compromised dialysis modality experience. 

“In addition, the recommendations in the position paper would move toward eliminating qualified nephrology registered nursing oversight that is essential to successful home dialysis therapies and patient safety,” according to the release.

In a response to the statement released by ANNA, Tonya Saffer, vice president of government affairs and market access for Outset Medical and an author of the IKC position paper, said it “put a spotlight on the exponential innovation that has revolutionized treatment options for dialysis patients over the last decade. What hasn’t changed is the need for skilled, trained practitioners to bring innovation and quality care to the patients who need it most.

“Nephrology nurses, nephrologists and skilled providers are a critical part of the patient support team; we fully support their roles in the clinics and at home.”

Nursing shortage

The changes proposed in the IKC position paper are reaction to a “rapidly increasing” shortage of nurses, the authors wrote.

“The outlook for nephrology nurses is especially troubling. ... High turnover is problematic because competent nephrology nurses require between (3) and (9) months of additional experience,” the authors wrote. “In addition, existing regulations require that nurses conduct home dialysis training, leading to the interpretation that the nurse must deliver all aspects of training, despite other care team members having applicable skills and training.

“This situation places an additional burden on nurses, making the shortage an additional challenge for expanding home dialysis.”

However, ANNA said reducing the role of nursing for patient training sets a “dangerous” precedent. 

“Of particular concern to ANNA is the recommendation to ‘remove the requirement that RNs conduct training’ and maintain a structured ‘oversight and participation’ in the practice of home dialysis. This is a dangerous and alarming alternative to the existing home dialysis management and presents a threat to patient safety. 

“A sustainable home dialysis process starts with education and training by a qualified nephrology-registered nurse,” ANNA said in the release. “Involving the nephrology-registered nurse at the beginning of the process leads to development of a professional patient relationship that fosters trust, familiarity and communication. This is an important step in identifying learning needs and managing patient therapy challenges. 

 

“Early identification of challenges and learning needs is imperative to long-term therapy success.”

Miriam Godwin, public policy director for the NKF and an author of the IKC paper, told Healio Nephrology that the nursing shortage is the main impetus for the proposed changes.

“Our community continues to have a practical problem,” wrote Godwin. “There are simply not enough nephrology nurses to grow home dialysis, especially not now when the pandemic has created severe workforce shortages in some parts of the country. 

“Patient safety is of the utmost concern to all of us. We owe it to patients to preserve their safety, provide care that aligns with their values and preferences, and act creatively to find novel and more meaningful ways of providing that care. We can achieve all three at once while acknowledging the practical realities that constrain us. 

“We very much hope to work with ANNA to pursue a path forward that meets all of patients’ needs and desires.”

 

Did this answer your question?

 

More News

 

Kidney Products

 

Register as a kidney donor to save someone like 4-year-old Alex

A registration site to help find a very closely matched kidney donor has opened to help save lives like that of 4-year-old Alex. Learn more here.

Alex is a 4-year-old boy in need of a kidney transplant after both were removed due to nephrotic syndrome. He was diagnosed in April of 2020 and has been on dialysis since November 2021. He is in need of a kidney so he can live and go back to school, he just wants to get back to playing with his friends and not feeling tired all the time.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


 
 

Did this answer your question?

 

More News

 

Kidney Products

 

Safety violations, resource shortages put Arizona dialysis patients at heightened risk

Dried blood, dust and grime found encrusted on 21 out of 25 dialysis stations at the Fresenius Kidney Care East Tucson dialysis clinic. 

Improperly disinfected dialysis stations and catheter hubs, which provide access to a patient’s bloodstream, identified repeatedly at DaVita Desert Mountain Dialysis Center in Scottsdale. 

Failure to follow a doctor’s treatment orders for two separate patients, leading to the potential for “increased mortality” at Fresenius Kidney Care Central Phoenix.

Since 2019, nearly three-quarters of Arizona’s 130 outpatient dialysis clinics were cited for lapses in protocols designed to keep patients safe, an AZCIR analysis of state inspection data shows. Some facilities are repeat offenders, with recurring infection control and safety violations dating back years.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


Such deficiencies are concerning at dialysis clinics because treatment requires a port with direct access to a person’s bloodstream, making patients particularly vulnerable to life-threatening infections as they typically visit a clinic three times a week for four hours at a time.  

End-stage renal disease, often the result of chronic kidney disease from diabetes, congenital kidney issues or hypertension, means a person’s kidneys no longer function well enough to filter waste and fluid from blood on their own. For these patients, treatment is a matter of life or death: A kidney transplant or ongoing dialysis treatment is needed for survival.

“Your life changes in a blink of an eye, and I think that can be really traumatic,” former dialysis patient Sachi Kuwahara said of transitioning to the treatment. This stress, she said, makes it hard for patients to proactively approach problems they may see at a clinic.

The Arizona Department of Health Services, the agency responsible for inspecting dialysis clinics, said it has done its part to consistently inspect and issue citations, at times levying fines up to $30,000 for repeat problems. But records obtained by AZCIR show that dialysis companies can negotiate those fines down by an order of magnitude, at times by hundreds of thousands of dollars. 

Records also reveal that the size of the fine does not always match the severity of the citation. Fines of between $250 and $1,250 were levied against clinics in seven instances after “actual harm” to patients occurred.

The nationwide medical staffing and supply shortages from COVID-19 have also reached dialysis clinics, further compounding the risks to patients. Experts are calling the lack of resources critical as the now two-year-old pandemic is straining the outpatient dialysis system. 

“The lack of dialysis care in the state right now during the pandemic is a significant issue,” said Colby Bower, the former assistant director of public health licensing services at the Arizona Department of Health Services, who left the agency in early 2022. “Hospitals are having to keep patients longer because they can't get them into an outpatient dialysis center because they have no staff.”

Mark Canavan, a 48-year-old from Surprise who has been on dialysis in Arizona since 2019, said he has noticed a change in his care since the pandemic started. 

The process of going to outpatient dialysis even before the pandemic brought about “profound exhaustion,” stress and extreme medical risks, he said. Now, it’s gotten worse. 

”There is no question that there has been a deleterious effect on myself and my fellow patients,” Canavan said. Despite the “almost heroic” efforts of dialysis staff at his clinic, he said he fears “the level of care that we once received may never return.”

Chronic kidney disease affects an estimated 37 million people in the U.S., or roughly 15% of the population. Nationwide, nearly 500,000 people require dialysis multiple times a week. 

People 65 and older make up the largest proportion of those with kidney disease, and research shows the condition disproportionately impacts people of color: Black people are almost four times as likely to have kidney failure as white people in the U.S., and about 14% of Hispanic people in the U.S. suffer from some form of chronic kidney disease.

Congress passed a law in October 1972 to create the National End Stage Renal Disease Program, which extends Medicare benefits to those who need dialysis. In the 50 years since its creation, the number of patients has skyrocketed, and the program now spends $51 billion per year on Medicare-related expenditures. Medicare covers 80% of the cost of dialysis, so supplemental insurance is needed to fill the gap. 

In Arizona, there are more than 17,000 people with end-stage renal disease, with roughly 60% of them seeking treatment among the state’s 130 Medicare-certified outpatient clinics. While dialysis patients tend to follow the state’s demographic breakdown, Native American patients are disproportionately represented when compared to their share of the state’s population.

Kuwahara, the former dialysis patient who moved to Arizona in 2017 to have a better chance for a kidney transplant, experienced first-hand the challenges patients can face in Arizona clinics.

The risks and stress of dialysis are something she has dealt with since she was young. Kuwahara was born with a kidney disease called focal segmental glomerulosclerosis, which damages the kidneys’ ability to filter waste from blood and can cause kidney failure. 

“When I was born, one of my kidneys was already not functioning, and then the other one was barely functioning. And at the age of 6, my kidneys completely failed,” she said. She had her first kidney transplant from a cadaver at age 9, but she needed another transplant 23 years later. 

Kuwahara said she immediately noticed a difference in treatment protocols at Phoenix clinics after moving here from California. 

First, she said, a clinic doctor took her off of medication that was helping her. After switching facilities, she said a tech at that clinic “wasn’t really following the safety protocol” after she noticed him letting the tip of the needle touch other surfaces—which she felt was an infection risk.

Her next clinic, though, made 2018 “the hardest year of my life in terms of being on dialysis.” 

At U.S. Renal Care Northeast Phoenix, Kuwahara said she encountered issues from staff not changing their gloves between patients to ignoring machine safety alarms during treatments. Staffers were also condescending and verbally abusive to her, she said.

One staff member “would make fun of me when they were putting the needles in,” because she looked away, Kuwahara said. She filed complaints with the clinic administrator and the End Stage Renal Disease Network, which coordinates between facilities and the federal government. 

A representative from U.S. Renal Care said over email that officials were “unable to provide specific comment on this person’s alleged experience in 2018” and are committed to patient safety and high quality care. 

According to ADHS records, U.S. Renal Care Northeast Phoenix received citations for infection control problems, among other issues, during state inspections in December 2019 and February 2021

Companies negotiate fines through “back and forth”

Dialysis centers must be certified by the state and the Centers for Medicare and Medicaid Services. ADHS conducts the related inspections in Arizona. 

If deficiencies are found, ADHS requires a plan of correction from the facility. Citations can also lead to a recommended fine, with a maximum penalty of up to $500 per violation for each day it occurs. 

An AZCIR review of enforcement action referrals showed that fines were recommended at 31 facilities from January 2019 through January 2022. In four separate instances involving clinics owned by DaVita Kidney Care and Fresenius Medical Care, multibillion dollar companies that combined operate more than 85% of Arizona’s outpatient dialysis clinics, the fines were negotiated down to far lower amounts than inspectors initially recommended. 

At Fresenius Kidney Care Arcadia in Phoenix, for example, inspectors recommended fines totaling $219,500 in March 2020, or $500 per day for 439 days, for a catheter infection control violation. The same violation was found during inspections in 2016, 2017, 2018 and again in 2020. 

In correspondence obtained by AZCIR, lawyers representing the Arcadia clinic challenged the recommended fine in a 12-page letter to ADHS. The case was settled in March 2021, when the company agreed to pay a $30,000 fine, according to the state licensing database. The most recent federal inspection of the facility didn’t find any violations.

DaVita Tucson East Dialysis had an infection control fine reduced to $20,000 from $193,000 in 2021. In Scottsdale, the DaVita Desert Mountain Dialysis Center had a $217,050 fine reduced to $6,000 for infection control and other violations in 2022. DaVita Power Road Dialysis in Mesa also had a recommended fine reduced from $83,750 to $5,000 this year, after inspectors found improperly disinfected catheters. 

Arizona Department of Health Services spokesperson Steve Elliott did not provide specific answers to repeated questions about how and why fines are reduced, instead writing in an emailed statement that “Settlements are negotiated, and the amount can come down from the recommendation through that back and forth.” 

Some dialysis clinics are fined smaller dollar amounts for issues that may be serious but have not been linked directly to patient harm or involved repeat violations, according to former ADHS licensing director Bower.

But AZCIR’s review of enforcement action referrals from the past three years indicates that patients have experienced direct health impacts from violations that included fines as low as $250. Seven clinics were cited for infractions that were classified in the third tier of a four-tier severity category, meaning actual harm occurred to patients as a direct result of deficient care. 

DaVita Brookwood Dialysis Center, a clinic in Glendale, was fined $500 in 2019 because problems were found with blood flow rate and oxygen levels during treatments that led to a patient feeling “shortness of breath, dizziness, nausea and cardiac symptoms'' in 17 instances, for example. 

When asked why this fine was $500 when actual patient harm occurred on 17 separate occasions, ADHS spokesperson Elliott wrote: “The $500 per occurrence (not per day) maximum fine applies to actual patient harm. For your background, reports of a patient being uncomfortable do not constitute patient harm.”

DaVita spokesperson Courtney Culpepper wrote in an emailed statement that the company is “committed to resolving items identified by the state and to working with them on better communications around the survey process going forward.” She did not address specific deficiencies found or fines levied by state inspectors. 

Fresenius Kidney Care spokesperson Brad Puffer also declined to comment on specific fines, instead writing in an emailed statement, “While our quality standards often exceed the hundreds of state and federal requirements, we work hard to take corrective action when any issue is identified.”

Limited patient choice with Arizona dialysis clinics

Of the 130 Medicare-certified outpatient dialysis clinics scattered throughout Arizona, about 75% are concentrated in the Phoenix and Tucson metro areas, giving patients limited choices if they live outside Arizona’s dense urban cores. 

When Sachi Kuwahara wanted to change to a new clinic after her experience at U.S. Renal Care Northeast Phoenix, she said it wasn’t easy. “A lot of the clinics are full and they have a waiting list,” she said, even before the pandemic. 

Paul Conway, chair of policy and global affairs at the American Association of Kidney Patients, a kidney patient education and advocacy group, said decision-making in dialysis care has largely been “centered around facilities and doctors” for more than four decades. He said the idea of patients choosing the facility is a relatively new idea—one supported by his group. But patient surveys indicate they can also be limited by location and access to transportation. 

For patients, it also can be difficult to figure out which facility to choose, or to know if the treatment provided is safe or effective. State and federal rating systems have substantial differences, including databases that show a variety of safety and quality metrics. 

“I don't think there's an effort to hide the ball,” Conway said, but there hasn’t been a proactive effort to make data available to patients and families, either.

“The culture that's present in a facility, that is the determinant, the driver of patient safety,” said Dr. Alan Kliger, a professor of medicine at Yale School of Medicine and the chair of the American Society of Nephrology’s Excellence in Patient Care initiative. While health department inspections are important, he said, it is vital that dialysis companies “do what we call a root cause analysis” of clinic issues rather than just pointing blame at an individual. 

There are two federal and state databases where patients and their families can search online for ratings and safety information on outpatient dialysis clinics.

The U.S. Centers for Medicare and Medicaid Services provides an online databasewhere users can compare facilities. The website shows two types of ratings: one for quality and another based on patient surveys. These ratings are based on a five star system, with three stars representing the national average. The quality rating system includes a series of “quality of care” measures ranging from avoidance of hospitalization and deaths to quality of waste removal from the blood. 

State health department licensing inspections do not show up on this website. In Arizona, they can be found at azcarecheck.com. The website displays the past three years of compliance surveys and enforcement actions. Dialysis clinics are listed under medical facilities.

Kliger said it is important to look at all factors involved, such as questioning whether there is an appropriate amount of staff, sufficient training and testing, and quality of leadership, for example. 

Large dialysis companies are aware of this process, he added, but “my experience has been some, I think, do a better job at it than others.”

In order to address concerns about issues with dialysis and kidney disease in Arizona, ADHS has worked since 2013 to gather national and state-level stakeholders once a year at a conference called the ADVICE Collaborative. This multidisciplinary gathering of dialysis and other end-stage renal disease health care providers is meant to “share and gain knowledge on best practices in the areas of patient engagement, emergency preparedness, and infection prevention.”

ADHS spokesperson Elliott said in a statement that feedback from this collaborative has been “consistently positive” and that it has been recognized nationally by the U.S.  as a “best practice.”

“They should get a lot of credit for that,” Conway said about Arizona’s collaborative conference. “I wish every state would do what Arizona has tried to do and has done for the past several years.”

Pandemic adds risk, causes critical shortages

In addition to COVID-19 posing a serious risk to immunocompromised patients who receive treatment in a congregate setting, fallout from the pandemic has caused critical supply and staffing shortages in dialysis clinics across the U.S. 

About 15,000 more dialysis patients died in 2020 than is typical, according to the United States Renal Data System. Experts think this is likely because of COVID.

“We've actually seen a decline in the total number of patients in the United States on dialysis. Dialysis patient mortality rates have been very high,” said Dr. Paul Palevsky, a professor of medicine at the University of Pittsburgh and president of the National Kidney Foundation

This is the first time patient numbers have declined in the 50-year history of the Medicare-funded end-stage renal disease program, he said. 

A January 2022 joint release from the National Kidney Foundation and the American Society of Nephrology points out that “COVID-19 continues to run rampant through dialysis facilities,” and there are staff and supply shortages that have “resulted in dialysis facility closures and backlogs in moving patients among dialysis, hospitals, and Skilled Nursing Facilities.” 

“It's high intensity, high risk, and you have to be self aware,” Conway said about dialysis treatment at outpatient clinics. The risks to patients have been particularly high since the start of the pandemic, he added, in part because “our concern has been that those people at the point of care have not been fully resourced.”

Current dialysis patient Mark Canavan said he looked into changing facilities from his Fresenius clinic in the West Valley over the past year, but he “couldn’t even get a tour” of other facilities because they didn’t have space, he said. 

He said he has noticed “too many patients for not enough staff, unforgiving schedules, condensed operating hours and perhaps most ridiculous of all being required to work while being demonstrably ill” at his current clinic. 

He is concerned more than ever about the safety of his fragile bloodstream access port, which has ruptured more than once, a complication that is considered a medical emergency because it can result in severe, difficult to stop bleeding. 

A recently published survey in the Nephrology Nursing Journal conducted during the pandemic shows 62% of respondents feel burned out from work. More than one-quarter of nephrology nurses surveyed agreed that the size of their workload caused them to miss “an important change in a patient’s condition.” 

In his 50 years as a nephrologist, Kliger said he has never seen such a severe staffing crisis in dialysis. Currently, he is the co-chair of the COVID-19 response group for the American Society of Nephrology.

He said staff numbers are down 25 to 40% in some places. “And why are they down? In part, because people have left the profession and part it's because after two years, people say ‘I can't stand it anymore.’” 

Clinics have been left to reduce hours and close clinics in order to concentrate patients where there is enough staff, he added. 

Non-profit dialysis provider Dialysis Clinic, Inc, which has four clinics in Arizona, wrote in an emailed statement that it has experienced some staffing challenges but has been able to meet patient needs using traveling nurses and managers filling in.

DaVita spokesperson Courtney Culpepper wrote in an email that “staffing challenges and supply disruptions are impacting all providers,” but care has been “continually accessible” across Arizona. 

Brad Puffer, Fresenius spokesperson, referred AZCIR to a company statement that said the company has pulled in regional National Guard members “where needed” and “accelerated local hiring efforts” to solve these issues.

Kuwahara no longer needs to seek ongoing dialysis treatments: She got a new kidney in December 2019, right before the pandemic swept the globe. 

She has decided to change careers moving forward, based in large part after her experience with a hard-to-reach social worker at U.S. Renal Care Northeast Phoenix. She is now finishing pre-requisite courses for a degree in social work so she can become a dialysis clinic social worker herself.

Clinics have social workers to help patients cope with the stress of dialysis and connect them with programs that could help them outside of the dialysis chair, like free rides and dental examinations. 

“Your physical health and your mental health are intertwined, and for a lot of patients, going into dialysis can be extremely hard,” she said, so her next goal is to help them navigate that world. 

“This is something that I really want to do.”

This report was first published by the Arizona Center for Investigative Reporting.

 
 

Did this answer your question?

 

More News

 

Kidney Products

 

Actress Sarah Hyland says she 'felt suicidal' after her first kidney transplant failed but covered up the pain because she didn't want to seem 'pathetic'

Sarah Hyland said she 'felt suicidal' after her first kidney transplant failed.

The Modern Family actress, 31, has kidney dysplasia, which affects the structure of the organ, and she recalled how low she felt having to undergo dialysis three times a week after her body rejected the first donated organ she had received.

'That's where I felt suicidal. I would avoid going into [organ] rejection and being on dialysis at all costs,' she said during Monday's episode of the Quitters Podcast.


Subscribe

Subscribe to the KidneyBuzz Diet Newsletter to help improve diet, maintain kidney function, and build greater energy levels, if possible.


She recalled: 'Just energetically I was like, "This is just hard for me to do anymore. And it would just be easier for everyone else too."

Hyland, who has since undergone a second and successful transplant, did her best to 'put on a show' because she didn't want to be seen as 'weak and pathetic.'

She added: 'When you have grown up your entire life having health issues and always being in pain, you have to learn how to have thick skin, put on a show.'

The actress pointed out that 'otherwise you're just going to be looked at as a really weak and pathetic and sad person.'

Hyland also expressed that she was not looking for sympathy while speaking out about her health issues. 

'I don't like to victimize myself. I don't like other people to victimize me. I had almost 27 years of putting on a show, whether it was on Broadway or in my family living room.'   

 
 

Did this answer your question?

 

More News

 

Kidney Products